Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibiotic Selection00:57

Antibiotic Selection

61.8K
Overview
61.8K
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

515
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
515
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

883
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
883
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.1K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

824
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
824
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

994
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
994

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The changing picture of community acquired urinary tract infections in the US: a daunting prospect.

Expert review of anti-infective therapy·2026
Same author

Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies.

Infectious diseases and therapy·2026
Same author

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same author

Clinical application of live biotherapeutic products in infectious diseases.

Frontiers in microbiomes·2026
Same author

Vaccine ambassadors: An educational model to empower youth and spread awareness of vaccines in Detroit.

American journal of infection control·2026
Same author

Epidemiology, length of stay, and survival outcomes of <i>Candida auris</i> infections in a tertiary care center in the greater detroit area.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2025

Related Experiment Video

Updated: Mar 11, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.4K

Rethinking Strategies to Select Antibiotic Therapy in Clostridium difficile infection.

Teena Chopra1, Ellie J C Goldstein2,3, Sherwood L Gorbach4

  • 1Division of Infectious Diseases, Detroit Medical Center and Wayne State University, Detroit, Michigan.

Pharmacotherapy
|November 19, 2016
PubMed
Summary
This summary is machine-generated.

Clostridium difficile infection (CDI) recurrence poses a significant health threat. Focusing on preventing recurrence, rather than just initial severity, may guide better treatment choices for patients with CDI.

Keywords:
Clostridium difficile infectiondisease severityfidaxomicinrecurrence

More Related Videos

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

40.3K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.4K

Related Experiment Videos

Last Updated: Mar 11, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.4K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

40.3K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.4K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Public Health

Background:

  • Clostridium difficile infection (CDI) is a major global health concern, with recurrence significantly increasing morbidity, mortality, and economic costs.
  • Current treatment guidelines for CDI primarily rely on disease severity at diagnosis, but lack clear definitions and evidence linking initial severity to patient outcomes.
  • Reducing the risk of CDI recurrence is crucial for improving individual prognosis and mitigating broader economic impacts.

Purpose of the Study:

  • To evaluate the role of recurrence risk in guiding Clostridium difficile infection (CDI) treatment decisions.
  • To propose a treatment strategy prioritizing the prevention of CDI recurrence over initial disease severity assessment.

Main Methods:

  • The study presents data and expert opinion to support a novel approach to CDI treatment.
  • Analysis of factors influencing Clostridium difficile infection (CDI) recurrence and treatment outcomes.
  • Review of current treatment guidelines and their limitations regarding disease severity.

Main Results:

  • Patients identified as low risk for recurrence may be adequately treated with vancomycin or metronidazole.
  • Patients at higher risk for recurrence are likely to benefit more from fidaxomicin treatment.
  • Evidence suggests that preventing CDI recurrence may be a more effective strategy than solely managing initial disease severity.

Conclusions:

  • Treatment decisions for Clostridium difficile infection (CDI) should prioritize preventing recurrence.
  • A risk-stratified approach, considering recurrence potential, can optimize therapeutic choices.
  • Further prospective studies are warranted to validate treatment strategies aimed at reducing CDI recurrence.